Apo-lipoprotein A1 in the Endometria of Patients with Polycystic OvarySyndrome

Abstract

Objective: This clinical trial aimed at assessing the levels of apo-lipoprotein A1 in the endometria of patients with polycystic ovary syndrome (PCOS). Setting: El-Demerdash Hospital, over a 2 years period, between September 2015 and January 2017. Patients: this clinical trial involved 50 patients (age range 20-35 years) arranged into two equal groups. Group I (25 patients) which includes women with PCOS and were collected from the infertility outpatient clinic while group II (25 patients) parous women, they were presented to us due to any cause other than inability to conceive as a control group. Methods: Endometrial brushing was performed to get endometrial samples from all consented women. ELIZA was used to detect the expression of Apo-lipoprotein A1 (Apo A1) in the endometrial samples. Two endometrial samples were gathered from every patient, the first one was collected when the largest ovarian follicle is ≥ 20 mm (proliferative phase) while the second one was collected 5 days following the first one (secretory phase). Results: Interestingly, endometria of infertile women with PCOS had expressed apo-lipoprotein A1 in higher levels than the endometria of infertile women. Also, this study proved that the expression of this protein was more in the proliferative rather than secretory phase of the menstrual cycle (P value<0.05). Conclusion: It is apparent that there is an inverse relationship between apo-lipoprotein A1 and the degree of receptivity of the endometria in women with PCOS. Also, this clinical trial found a fluctuation of the level of this protein all through the menstrual cycle, being higher in the proliferative phase and less in the secretory phase when the endometrium is receptive for embryos (window of implantation).